Herein, we present and critically discuss the more recent evidence related to preclinical/prodromal markers associated with increased risk of PD, classified as clinical, genetic, environmental, biochemical, and neuroimaging, in GBA1 and LRRK2 non-manifesting carriers (NMC). Here, GBA1 is linked to Parkinson disease.